Founded by serial entrepreneur and CEO, Donal Devery, EnteraSense has developed a capsule that can detect bleeding in the gastrointestional tract. Post surgical patients who are at risk of further bleeding can have the capsule attached to their stomach to monitor and detect bleeding and thus ensure they get appropriate and quick treatment if needed. To complement this, patients who present in ER and have suspected GI bleeding can swallow the capsule for a quick and easy diagnosis. This will mitigate unnecessary endoscopies which are invasive and in a lot of circumstances unnecessary.
Devery, along with EnteraSense MD, Daragh Sharkey and Programme Manager Chiara Di Carlo, has licenced the groundbreaking technology from Harvard University in Boston. The NDRC-backed company has successfully run initial trials to prove and validate the capsule. EnteraSense will move towards ‘First in Human’ studies by Q3 2019 and hope to be commercial with FDA and CE approval by mid 2020.